We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-3.25%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.01B
AUM Growth
+$262M
Cap. Flow
-$162M
Cap. Flow %
-2.7%
Top 10 Hldgs %
51.52%
Holding
592
New
224
Increased
125
Reduced
42
Closed
159

Top Buys

Rank Stock Value
1
WAY
Waystar Holding Corp
WAY
+$107M
2
GILD icon
Gilead Sciences
GILD
+$99.5M
3
CVS icon
CVS Health
CVS
+$61M
4
BAX icon
Baxter International
BAX
+$57.9M
5
CGEM icon
Cullinan Oncology
CGEM
+$45.6M

Top Sells

Rank Stock Value
1
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$136M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$80.7M
3
SWTX
SpringWorks Therapeutics
SWTX
+$63.2M
4
OSCR icon
Oscar Health
OSCR
+$44.4M
5
VKTX icon
Viking Therapeutics
VKTX
+$38M

Sector Composition

Rank Sector Weight
1 Healthcare 83.29%
2 Industrials 0.69%
3 Technology 0.57%
4 Financials 0.44%
5 Consumer Discretionary 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$1.52B 25.23%
19,991,024
– –
VTRS icon
2
Viatris
VTRS
$20.1B
$227M 3.78%
21,395,496
+444
+0% +$4.91K
CNC icon
3
Centene
CNC
$32.8B
$176M 2.92%
2,650,122
+269,078
+11% +$19.6M
MRUS
4
DELISTED
Merus
MRUS
$163M 2.71%
2,749,401
+100,000
+4% +$4.84M
LRMR icon
5
Larimar Therapeutics
LRMR
$384M
$154M 2.56%
21,231,974
– –
CPRX
6
DELISTED
Catalyst Pharmaceutical
CPRX
$141M 2.35%
9,127,305
-3,512
-0% -$54.7K
AHCO icon
7
AdaptHealth
AHCO
$1.49B
$133M 2.21%
13,257,940
– –
RVMD icon
8
Revolution Medicines
RVMD
$39.6B
$120M 2%
3,090,073
– –
SGRY icon
9
Surgery Partners
SGRY
$2.09B
$112M 1.86%
4,707,287
+1,520,484
+48% +$39M
KURA icon
10
Kura Oncology
KURA
$964M
$111M 1.85%
5,411,571
– –
OSCR icon
11
Oscar Health
OSCR
$8.77B
$110M 1.83%
6,959,787
-2,413,310
-26% -$44.4M
BKD icon
12
Brookdale Senior Living
BKD
$3.58B
$107M 1.77%
15,612,264
– –
WAY
13
Waystar Holding Corp
WAY
$4.27B
$106M 1.77%
+4,952,004
New +$107M
GILD icon
14
Gilead Sciences
GILD
$167B
$102M 1.7%
+1,491,000
New +$99.5M
NBIX icon
15
Neurocrine Biosciences
NBIX
$17.2B
$95.1M 1.58%
691,004
– –
SPRY icon
16
ARS Pharmaceuticals
SPRY
$695M
$94.3M 1.57%
11,077,927
– –
ACH
17
Accendra Health
ACH
$266M
$86M 1.43%
6,371,440
+1,493,852
+31% +$30.6M
ALHC icon
18
Alignment Healthcare
ALHC
$4.26B
$85.2M 1.42%
10,901,485
+2,630,788
+32% +$17.2M
IDYA icon
19
IDEAYA Biosciences
IDYA
$3.47B
$73.6M 1.23%
2,097,113
-533,179
-20% -$21.1M
HLVX
20
DELISTED
HilleVax
HLVX
$57.9M 0.96%
4,004,231
– –
CVS icon
21
CVS Health
CVS
$137B
$57.6M 0.96%
+975,000
New +$61M
CGEM icon
22
Cullinan Oncology
CGEM
$1.09B
$57.2M 0.95%
3,280,237
+2,141,706
+188% +$45.6M
BAX icon
23
Baxter International
BAX
$11.7B
$52.8M 0.88%
1,577,647
+1,571,506
+25,590% +$57.9M
EWTX icon
24
Edgewise Therapeutics
EWTX
$4.28B
$51.8M 0.86%
2,874,586
– –
BCRX icon
25
BioCryst Pharmaceuticals
BCRX
$2.36B
$50.3M 0.84%
8,135,804
+3,140,804
+63% +$17.3M
1
2 3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q2 2024 Portfolio in Review

As of Q2 2024, Deerfield Management held 592 positions worth $6.01B, up 4.6% from $5.75B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Deerfield Management's Q2 2024 filing shows 224 new, 125 increased, 42 reduced and 159 closed positions. Its largest new stake was Waystar Holding Corp: 4,952,004 shares worth $106M. The largest sale was Fusion Pharmaceuticals Inc. Common Shares, an estimated $136M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 89% a quarter earlier, followed by Industrials and Technology.

  • Deerfield Management's largest Q2 2024 buy was Waystar Holding Corp: 4,952,004 shares worth $106M.
  • Deerfield Management added most to Baxter International in Q2 2024, an estimated $57.9M increase.
  • Deerfield Management's biggest Q2 2024 reduction was Oscar Health, cutting an estimated $44.4M.
  • Deerfield Management fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $136M.
  • Deerfield Management's ten largest holdings make up 52% of its $6.01B portfolio in Q2 2024.
  • Deerfield Management opened 224 new positions and closed 159 in Q2 2024.
  • Deerfield Management's portfolio value rose 4.6% quarter-over-quarter to $6.01B.

Based on Deerfield Management's 13F filing for Q2 2024, filed 14 Aug 2024.